Reference health
Recent Advances Targeting CCR5 for Cancer and Its Role in Immuno-Oncology
82/82 checkable references clean · checked 2026-07-23
Every reference with a DOI in the deposited reference list resolved to a known work in Crossref or DataCite at the dated check, and none carried a retraction, withdrawal, or removal notice.
10 without a DOI — not checked. A reference deposited without a DOI is never matched by title or guessed at; it stays outside the checked set, and this line discloses that.
The 82 checked references that resolve
resolves10.1128/JVI.73.5.4145-4155.1999
Differential Inhibition of Human Immunodeficiency Virus Type 1 Fusion, gp120 Binding, and CC-Chemokine Activity by Monoclonal Antibodies to CCR5
resolves10.1158/0008-5472.CAN-17-0915
CCR5 Governs DNA Damage Repair and Breast Cancer Stem Cell Expansion
resolves10.1126/science.273.5283.1856
Genetic Restriction of HIV-1 Infection and Progression to AIDS by a Deletion Allele of the
<i>CKR5</i>
Structural Gene
resolves10.1038/382722a0
Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene
resolves10.1056/NEJMoa0803154
Subgroup Analyses of Maraviroc in Previously Treated R5 HIV-1 Infection
resolves10.4049/jimmunol.182.3.1746
Disruption of CCR5-Dependent Homing of Regulatory T Cells Inhibits Tumor Growth in a Murine Model of Pancreatic Cancer
resolves10.1016/j.bmcl.2010.06.003
Anibamine, a natural product CCR5 antagonist, as a novel lead for the development of anti-prostate cancer agents
resolves10.3892/etm.2015.2911
Downregulation of CCR5 inhibits the proliferation and invasion of cervical cancer cells and is regulated by microRNA-107
resolves10.1101/gr.089417.108
Targeted genome editing in human cells with zinc finger nucleases constructed via modular assembly
resolves10.1158/1535-7163.MCT-07-0114
Glycosaminoglycans and their synthetic mimetics inhibit RANTES-induced migration and invasion of human hepatoma cells
resolves10.1124/jpet.111.179531
Identification and Characterization of INCB9471, an Allosteric Noncompetitive Small-Molecule Antagonist of C-C Chemokine Receptor 5 with Potent Inhibitory Activity against Monocyte Migration and HIV-1 Infection
resolves10.1158/0008-5472.CAN-17-0348
CCR5+ Myeloid-Derived Suppressor Cells Are Enriched and Activated in Melanoma Lesions
resolves10.1158/0008-5472.CAN-14-0612
CCR5 Receptor Antagonists Block Metastasis to Bone of v-Src Oncogene–Transformed Metastatic Prostate Cancer Cell Lines
resolves10.1016/j.ccell.2016.03.005
Tumoral Immune Cell Exploitation in Colorectal Cancer Metastases Can Be Targeted Effectively by Anti-CCR5 Therapy in Cancer Patients
resolves10.1007/s12032-015-0607-x
CCR5 blockage by maraviroc induces cytotoxic and apoptotic effects in colorectal cancer cells
resolves10.1002/path.5207
High expression of CCR5 in melanoma enhances epithelial–mesenchymal transition and metastasis via TGFβ1
resolves10.3324/haematol.2018.196725
CCR5 antagonism by maraviroc inhibits Hodgkin lymphoma microenvironment interactions and xenograft growth
resolves10.1111/jop.12736
Clinicopathological significance of chemokine receptor (<scp>CCR</scp>1, <scp>CCR</scp>3, <scp>CCR</scp>4, <scp>CCR</scp>5, <scp>CCR</scp>7 and <scp>CXCR</scp>4) expression in head and neck squamous cell carcinomas
resolves10.3390/ijms19051477
Inhibition of the CCL5/CCR5 Axis against the Progression of Gastric Cancer
resolves10.1016/j.cyto.2018.04.027
Autocrine CCL5 promotes tumor progression in esophageal squamous cell carcinoma in vitro
resolves10.1038/s41598-018-19643-0
CCR5/CCL5 axis interaction promotes migratory and invasiveness of pancreatic cancer cells
resolves10.1158/1078-0432.CCR-06-0074
The Chemokine CCL5 as a Potential Prognostic Factor Predicting Disease Progression in Stage II Breast Cancer Patients
resolves10.1016/j.ygyno.2006.01.029
Elevated serum RANTES levels in patients with ovarian cancer correlate with the extent of the disorder
resolves10.1007/s12029-014-9652-5
Serum Chemokine Ligand 5 (CCL5/RANTES) Level Might be Utilized as a Predictive Marker of Tumor Behavior and Disease Prognosis in Patients with Gastric Adenocarcinoma
resolves10.18632/oncotarget.9187
Serum VEGF-A and CCL5 levels as candidate biomarkers for efficacy and toxicity of regorafenib in patients with metastatic colorectal cancer
resolves10.1371/journal.pone.0028842
CCL5 Neutralization Restricts Cancer Growth and Potentiates the Targeting of PDGFRβ in Colorectal Carcinoma
resolves10.1002/ijc.23401
Gastric cancer cells exploit CD4+ cell‐derived CCL5 for their growth and prevention of CD8+ cell‐involved tumor elimination
resolves10.1007/s12307-014-0148-4
Microenvironmental Influences on Metastasis Suppressor Expression and Function during a Metastatic Cell’s Journey
resolves10.1038/nature06188
Mesenchymal stem cells within tumour stroma promote breast cancer metastasis
resolves10.1096/fj.201700237RR
Endothelial cells promote triple‐negative breast cancer cell metastasis
<i>via</i>
PAI‐1 and CCL5 signaling
resolves10.1016/j.celrep.2017.10.104
CCR5 Directs the Mobilization of CD11b+Gr1+Ly6Clow Polymorphonuclear Myeloid Cells from the Bone Marrow to the Blood to Support Tumor Development
resolves10.4049/jimmunol.1201018
Tumor-Infiltrating Monocytic Myeloid-Derived Suppressor Cells Mediate CCR5-Dependent Recruitment of Regulatory T Cells Favoring Tumor Growth
resolves10.1038/s41419-019-1508-2
Bone marrow-derived mesenchymal stem cells promote colorectal cancer progression via CCR5
resolves10.1158/0008-5472.CAN-08-2281
Chemokine Expression in Melanoma Metastases Associated with CD8+ T-Cell Recruitment
resolves10.1158/0008-5472.CAN-11-2493
Tumor-Derived Chemokine CCL5 Enhances TGF-β–Mediated Killing of CD8+ T Cells in Colon Cancer by T-Regulatory Cells
resolves10.1038/nature04651
Chemokines enhance immunity by guiding naive CD8+ T cells to sites of CD4+ T cell–dendritic cell interaction
resolves10.1080/2162402X.2016.1150398
Maraviroc decreases CCL8-mediated migration of CCR5<sup>+</sup>regulatory T cells and reduces metastatic tumor growth in the lungs
resolves10.1084/jem.20141836
CCL2-induced chemokine cascade promotes breast cancer metastasis by enhancing retention of metastasis-associated macrophages
resolves10.1016/j.celrep.2018.04.007
A Unidirectional Transition from Migratory to Perivascular Macrophage Is Required for Tumor Cell Intravasation
resolves10.1016/j.cell.2018.05.060
Single-Cell Map of Diverse Immune Phenotypes in the Breast Tumor Microenvironment
resolves10.1053/j.seminoncol.2015.05.011
The Next Hurdle in Cancer Immunotherapy: Overcoming the Non–T-Cell–Inflamed Tumor Microenvironment
resolves10.1007/s00262-011-1172-6
An immune-active tumor microenvironment favors clinical response to ipilimumab
resolves10.1158/1078-0432.CCR-15-0244
Differential Expression of Immune-Regulatory Genes Associated with PD-L1 Display in Melanoma: Implications for PD-1 Pathway Blockade
resolves10.1186/s40425-017-0290-x
Peripheral and local predictive immune signatures identified in a phase II trial of ipilimumab with carboplatin/paclitaxel in unresectable stage III or stage IV melanoma
resolves10.4049/jimmunol.1200266
The Indispensable Role of CCR5 for In Vivo Suppressor Function of Tumor-Derived CD103+ Effector/Memory Regulatory T Cells
resolves10.1126/scitranslmed.3007974
Disruption of CXCR2-Mediated MDSC Tumor Trafficking Enhances Anti-PD1 Efficacy
resolves10.1007/s12307-011-0094-3
The Tumor-Promoting Flow of Cells Into, Within and Out of the Tumor Site: Regulation by the Inflammatory Axis of TNFα and Chemokines
resolves10.1186/s12885-017-3817-0
CCL5-CCR5 interactions modulate metabolic events during tumor onset to promote tumorigenesis
resolves10.1158/0008-5472.CAN-14-3394
Metastasis Suppressors Regulate the Tumor Microenvironment by Blocking Recruitment of Prometastatic Tumor-Associated Macrophages
resolves10.18632/oncotarget.9213
CCL5 promotes VEGF-C production and induces lymphangiogenesis by suppressing miR-507 in human chondrosarcoma cells
resolves10.1182/blood-2008-07-166934
Toll-like receptor 4 in lymphatic endothelial cells contributes to LPS-induced lymphangiogenesis by chemotactic recruitment of macrophages
resolves10.1098/rsob.160122
CCL5 activation of CCR5 regulates cell metabolism to enhance proliferation of breast cancer cells
resolves10.1158/0008-5472.CAN-16-2913
Targeting Autocrine CCL5–CCR5 Axis Reprograms Immunosuppressive Myeloid Cells and Reinvigorates Antitumor Immunity
resolves10.18632/oncotarget.10227
Blockade of the chemokine receptor, CCR5, reduces the growth of orthotopically injected colon cancer cells via limiting cancerassociated fibroblast accumulation
resolves10.1007/s10753-015-0186-1
CCR5 Blockade Suppresses Melanoma Development Through Inhibition of IL-6-Stat3 Pathway via Upregulation of SOCS3
resolves10.1155/2018/8543763
Molecular Pathogenesis of Nonalcoholic Steatohepatitis- (NASH-) Related Hepatocellular Carcinoma
resolves10.1016/j.trsl.2018.01.004
Maraviroc improves hepatic triglyceride content but not inflammation in a murine nonalcoholic fatty liver disease model induced by a chronic exposure to high-fat diet
resolves10.1371/journal.pone.0053992
Maraviroc, a CCR5 Antagonist, Prevents Development of Hepatocellular Carcinoma in a Mouse Model
resolves10.1172/jci.insight.92111
An activated Th17-prone T cell subset involved in chronic graft-versus-host disease sensitive to pharmacological inhibition
resolves10.1016/j.bbmt.2017.10.041
PRO 140 Monoclonal Antibody to CCR5 Prevents Acute Xenogeneic Graft-versus-Host Disease in NOD-scid IL-2Rynull Mice
resolves10.1080/13543784.2018.1442436
Cenicriviroc for the treatment of non-alcoholic steatohepatitis and liver fibrosis
resolves10.1182/blood-2016-08-735076
Clinical and immunologic impact of CCR5 blockade in graft-versus-host disease prophylaxis
The 10 references without a DOI — listed, not checked
no DOI — not checkedPrimary efficacy results of PRO 140 SC in a pivotal phase 2b/3 study in heavily treatment-experienced HIV-1 patients
no DOI — not checkedA chemokine receptor antagonist inhibits experimental breast tumor growth
no DOI — not checkedThe saponin DT-13 inhibits gastric cancer cell migration through down-regulation of CCR5-CCL5 axis
no DOI — not checkedC-C motif chemokine receptors in gastric cancer
no DOI — not checkedTreatment with the C-C chemokine receptor type 5 (CCR5)-inhibitor maraviroc suppresses growth and induces apoptosis of acute lymphoblastic leukemia cells
no DOI — not checkedCorrelation of tissue and plasma RANTES levels with disease course in patients with breast or cervical cancer
no DOI — not checkedThe CC chemokine RANTES in breast carcinoma progression: regulation of expression and potential mechanisms of promalignant activity
no DOI — not checkedPan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy
no DOI — not checkedMechanisms of primary and secondary resistance to immune checkpoint inhibitors in cancer
no DOI — not checkedLeronlimab, a humanized monoclonal antibody to CCR5, blocks breast cancer cellular invasion and enhances cell death induced by DNA damaging chemotherapies
What this badge says. CiteStamped means the CHECKABLE references of this
work were clean at the dated check: each resolved to a known work in a public registry, and none
carried a retraction notice at that time. It says nothing about the quality, findings,
or importance of the work itself, and nothing about references deposited without a DOI.
checked 2026-07-23 — re-checked daily as this page is visited; titles and statuses come from Crossref and DataCite and are not part of the signed record
Embed this badge
Both snippets point at the live badge image and link back to this page. The badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.
<a href="https://citestamp.com/citestamped/10.1158/0008-5472.can-19-1167"><img src="https://citestamp.com/citestamped/10.1158/0008-5472.can-19-1167/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>
[](https://citestamp.com/citestamped/10.1158/0008-5472.can-19-1167)